511 filings
ARS
2023 FY
MRKR
Marker Therapeutics Inc
26 Apr 24
Annual report to shareholders
4:07pm
DEF 14A
MRKR
Marker Therapeutics Inc
Definitive proxy
26 Apr 24
4:05pm
8-K
MRKR
Marker Therapeutics Inc
8 Apr 24
Other Events
7:09am
8-K
MRKR
Marker Therapeutics Inc
25 Mar 24
Marker Therapeutics Reports Year-End 2023 Corporate and Financial Results
6:18pm
8-K
MRKR
Marker Therapeutics Inc
1 Mar 24
Termination of a Material Definitive Agreement
8:02am
8-K
q6ze4sj1
26 Feb 24
Entry into a Material Definitive Agreement
7:58am
8-K
26yqk60 ic
8 Jan 24
Marker Therapeutics Announces Clinical Program Updates and Pipeline Prioritization
8:30am
8-K
oqmkcos hnzd4l
11 Dec 23
Marker Therapeutics Announces Sustained Complete Response in First Lymphoma Patient Treated with MT-601 following CAR T Relapse
7:35am
8-K
urrmw27w6
20 Nov 23
Departure of Directors or Certain Officers
4:37pm
8-K
rl27dx
9 Nov 23
Marker Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates
5:03pm
8-K
gdiflumys5gwf6v6fw22
11 Sep 23
Marker Therapeutics Announces Complete Response in First Lymphoma Patient Treated with MT-601 after CAR T Relapse
7:10am
8-K
0d1wd9uhhz37 q9g9
14 Aug 23
Marker Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update
4:37pm
8-K
h9niv
7 Aug 23
Marker Therapeutics Reports Non-Clinical Proof-of-Concept Data and Update on Clinical Readiness for the MT-401 Off-the-Shelf Program
7:22am
8-K
at0pkq jw
10 Jul 23
European Medicines Agency Grants Orphan Drug Designation for MT-401 developed by Marker Therapeutics for the Treatment of AML Patients
7:09am
8-K
4e9r7ygu0 fdsww
3 Jul 23
Departure of Directors or Certain Officers
4:05pm
8-K
9taqiraojgm
30 Jun 23
Completion of Acquisition or Disposition of Assets
4:05pm
8-K
9ca33
26 Jun 23
Marker Therapeutics Reports MT-401 Non-Clinical Data in AML Cells after Hypomethylating Agent Administration
7:14am
8-K
biz9x9 psmw
12 Jun 23
Marker Therapeutics Announces First Lymphoma Patient Treated with MT-601 in Phase 1 Clinical Trial
7:09am